We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

55 hedge funds and large institutions have $313M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 16

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

7% less funds holding

Funds holding: 5955 (-4)

12% less capital invested

Capital invested by funds: $355M → $313M (-$42.2M)

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
1.26%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
10
Increased
21
Reduced
16
Closed
14
Calls
Puts
Net Calls
Net Calls Change

DCPH Hedge Fund Activity: Q1 2018 in Review

55 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2018, worth a combined $313M — down 12% from $355M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of DCPH and 10 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 21 added.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $22.4M. The largest seller was Millennium Management, cutting an estimated $12.3M.

  • 55 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2018, down from 59 in Q4 2017.
  • Funds reported $313M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2018, down 12% quarter-over-quarter.
  • 10 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2018 and 14 closed out, a net change of -4 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2018 was Fidelity Investments, an estimated $22.4M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2018 was Millennium Management, an estimated $12.3M sold.

Based on aggregated 13F filings for Q1 2018.